Edgewise Therapeutics, Inc.(EWTX)

POST44.210.000.00%17:33 EDT

44.21-0.51-1.14%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy
  Reuters · 08-24 20:02
  Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy
- Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
  TIPRANKS · 08-21
  Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
- Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan
  Dow Jones · 08-21
  Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan
- Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan
  TIPRANKS · 08-20
  Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan
- Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?
  Simply Wall St. · 08-20
  Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?
- Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich
  Simply Wall St. · 08-17
  Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich
- Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares
  Reuters · 08-15
  Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares
- Edgewise Therapeutics is Maintained at Neutral by Goldman Sachs
  Dow Jones · 08-12
  Edgewise Therapeutics is Maintained at Neutral by Goldman Sachs
- Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
  TIPRANKS · 08-11
  Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
- Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating
  MT Newswires Live · 08-07
  Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating
- Edgewise Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
  Reuters · 08-06
  Edgewise Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
- Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
  Benzinga Earnings · 08-06
  Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate
- Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
  Reuters · 08-06
  Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
- Edgewise Net Loss Widens 58.74% to $57.33 Million in Q2 FY26
  Reuters · 08-06
  Edgewise Net Loss Widens 58.74% to $57.33 Million in Q2 FY26
- Edgewise Therapeutics Q2 Operating Expenses USD 61.943 Million
  THOMSON REUTERS · 08-06
  Edgewise Therapeutics Q2 Operating Expenses USD 61.943 Million
- Edgewise Therapeutics Q2 Basic EPS USD -0.53
  THOMSON REUTERS · 08-06
  Edgewise Therapeutics Q2 Basic EPS USD -0.53
- Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
  Dow Jones · 08-06
  Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
- Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors
  TIPRANKS · 08-06
  Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors
- Edgewise Therapeutics is Maintained at Outperform by Evercore ISI Group
  Dow Jones · 07-20
  Edgewise Therapeutics is Maintained at Outperform by Evercore ISI Group
- Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
  TIPRANKS · 07-20
  Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI
Company Profile
Company Name
Edgewise Therapeutics, Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.edgewisetx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 08-06
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 08-06
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-16
  Major Issues Report
  Form 8-K/A - Current report: [Amend]
  Form 8-K/A - Current report: [Amend]
- 07-13
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-01
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 06-05
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-01
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 05-07
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 05-07
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

46.32

Open

45.22

Volume%

0.78

Low

44.02

44.72

T/O Rate

1.30%

To The Moon

Edgewise Therapeutics, Inc.(EWTX)

Company Profile

Most Discussed